Keyphrases
BRAF V600E
59%
Chemotherapy
32%
Oncological Networks
29%
Therapeutic Implications
29%
Medulloepithelioma
29%
Vemurafenib
29%
Prognostic Implications
29%
Pediatric Brain Tumor
29%
Extracranial
29%
National Cancer Institute
29%
Long-term Efficacy
29%
Immune System
29%
Central Nervous System Tumors
29%
Neurotoxicity
29%
Histone
29%
Immunotherapeutic Approaches
29%
Maribavir
29%
Multidrug-resistant
29%
Pediatric Cancer Patients
29%
Tumor
23%
Glioma
20%
Cytomegalovirus Viremia
19%
Pediatric
17%
Alternative Therapeutics
14%
Chimeric Antigen Receptor T-cell Therapy
14%
Monotherapy
14%
Site of Disease
14%
Neurological Effects
14%
Cancer Cells
14%
Vaccine Therapy
14%
Checkpoint Inhibitors
14%
Immunotherapeutics
14%
Inflammation
14%
Special Concern
14%
Neurological Complications
14%
Brain Tumor
14%
Confined Area
14%
Therapeutic Intervention
14%
Adoptive Immunotherapy
14%
Current Management
14%
BRAF V600E mutation
13%
Central Nervous System Cancer
11%
BRAF Inhibitor (BRAFi)
10%
Young Males
10%
End-organ Disease
9%
Older Patients
9%
4-year-olds
9%
Myelosuppression
9%
Clinically Significant
9%
Lymphoma
9%
Medicine and Dentistry
Pediatrics
100%
Ganglioglioma
88%
Central Nervous System Tumor
59%
Malignant Neoplasm
32%
Neoplasm
30%
Immunotherapy
29%
Vemurafenib
29%
Immune System
29%
Side Effect
29%
Histone
29%
Pleomorphic Xanthoastrocytoma
29%
Neurotoxicity
29%
Oncology
29%
Neuroepithelioma
29%
Childhood Cancer
29%
Benzimidavir
29%
Diseases
22%
Viremia
19%
Cytomegalovirus
19%
Surgery
15%
Neurological Complication
14%
Adoptive Immunotherapy
14%
Chimeric Antigen Receptor T-Cell Immunotherapy
14%
Cancer Cell
14%
Monotherapy
14%
Central Nervous System
14%
Pediatric Brain Tumor
14%
Cancer
14%
Bone Marrow Suppression
9%
Central Nervous System Cancer
7%
Brain Cancer
7%
Progression Free Survival
5%